A Disintegrin And Metalloproteinase 8 (ADAM8) has been implicated in the development and progression of several cancers. However, further studies are needed to determine the value of ADAM8 in ccRCC. The research aimed to investigate the prognostic and immunologic significance of ADAM8 in ccRCC from the perspective of bioinformatics.

Our research found that ADAM8 could have a significant impact on the development, progression, immunotherapy and prognosis of patients with ccRCC, and may be a promising prognostic and immunotherapeutic target. The study provides a new insights that may be useful in helping to manage ccRCC.

We analyzed the expression and prognosis of ADAM8 in ccRCC using The Cancer Genome Atlas and validated it with Gene Expression Omnibus and immunohistochemistry assay. Functional enrichment analysis was conducted to investigate the signaling pathways. And the relationship between ADAM8 and the tumor microenvironment was analyzed using the CIBERSORT algorithm. Furthermore, the study explored the response to immunotherapy of ccRCC by using The Cancer Immunome Atlas database data. Potential drugs for treating ccRCC were discovered using the Connectivity Map.

The expression of ADAM8 was significantly elevated in ccRCC tissues. CcRCC patients with higher levels of ADAM8 expression had poorer prognosis, and ADAM8 was shown to be an independent predictive risk factor for ccRCC. The functional enrichment analysis revealed relevant signaling pathways. Furthermore, we found that ADAM8 expression correlates strongly with the extent of immune cell infiltration and immunotherapy. Finally, 4 groups of potential drugs for the treatment of ccRCC were identified.